



RESEARCH

Open Access

Recurrence and prognostic factors in patients with aggressive fibromatosis. The role of radical surgery and its limitations

Emilio Bertani^{1*}, Alessandro Testori², Antonio Chiappa^{1,3}, Pasquale Misitano¹, Roberto Biffi⁴, Giuseppe Viale^{5,3}, Giovanni Mazzarol⁵, Tommaso De Pas⁶, Edoardo Botteri⁷, Gianmarco Contino¹, Francesco Verrecchia², Barbara Bazolli⁷ and Bruno Andreoni^{1,3}

Abstract

Background: Surgery is still the standard treatment for aggressive fibromatosis (AF); however, local control remains a significant problem and the impact of R0 surgery on cumulative recurrence (CR) is objective of contradictory reports.

Methods: This is a single-institution study of 62 consecutive patients affected by extra-abdominal and intra-abdominal AF who received macroscopically radical surgery within a time period of 15 years.

Results: Definitive pathology examination confirmed an R0 situation in 49 patients and an R1 in 13 patients. Five-year CR for patients who underwent R0 vs R1 surgery was 7.1% vs 46.4% ($P=0.04$) and for limbs vs other localizations 33.3% vs 9.9% ($P=0.02$) respectively. In 17 patients who had intraoperative frozen section (IFS) margin evaluation R0 surgery was more common (17 of 17 vs 32 of 45, $P=0.01$) and CR lower (five-year CR 0% vs 19.1%, respectively, $P=0.04$). However, in multivariate analysis only limb localization showed a negative impact on CR (HR: 1.708, 95% CI 1.03 to 2.84, $P=0.04$).

Conclusions: IFS evaluation could help the surgeon to achieve R0 surgery in AF. Non-surgical treatment, including watchful follow-up, could be indicated for patients with limb AF localization, because of their high risk of recurrence even after R0 surgery.

Keywords: Aggressive fibromatosis, Desmoid tumors, Surgery, Frozen sections, Local recurrence, Risk factors

Background

Among soft tissue neoplasms, desmoids tumors, also called aggressive fibromatosis, account for less than 3% (0.03 of all tumors). These neoplasms do not have metastatic potential but tend to locally infiltrate the musculo-aponeurotic structures [1]. Local control of aggressive fibromatosis (AF) remains a significant problem, with an average recurrence rate of 24 to 77% no matter what therapeutic modality is used [2]. Surgery is the primary therapy for extra-abdominal and abdominal wall desmoid tumors; however, the identification of informative prognostic factors, such as margins (R0 surgery),

localization, diameter and so on is still controversial. Of particular importance for the surgeon is the prognostic significance of R0 surgery in planning the width of resection, especially when the surgical site is challenging and surgery has the risk of short- and long-term postoperative complications. In addition, alternative approaches, such as radiotherapy [3,4], COX-2 inhibitors [5], anti-estrogens, interferon alpha, vitamin C [6], cytotoxic chemotherapy [7,8] and imatinib [9], have shown various degrees of efficacy. Observation alone is increasingly recommended for static lesions, given the morbidity associated with surgical resection and frequent disease recurrence [10,11]. Therefore, a consensus over the standard of care is limited and weakened by heterogeneous treatments and lack of large studies. In this context, the aim of the present study was to analyze the role

* Correspondence: emilio.bertani@ieo.it

¹Division of General and Laparoscopic Surgery, European Institute of Oncology, Via G. Ripamonti, 435, 20141, Milan, Italy
Full list of author information is available at the end of the article

and the limitations of radical surgery and the impact of the other risk factors for AF recurrence in a consecutive surgical series of patients homogeneously treated at a single institute.

Methods

From 1994 to 2010, 73 patients affected by AF were observed at the European Institute of Oncology and their records were extracted from the institute's tumor registry, a prospective desmoid tumor database containing 65 data fields. Eleven patients had a histologically confirmed diagnosis of AF in the resected specimen or pathology review in our institute. One patient was affected by familial adenomatous polyposis coli (FAP). Sixty-three patients underwent surgery (86.3%), while the remaining 10 patients were judged unresectable. Among this latter group, two cases underwent low-dose chemotherapy, three were given COX-2 inhibitors with or without tamoxifen, while four patients were put under observation. Of the 63 surgically treated patients, 62 (98%) received macroscopically radical surgery (R0 or R1 according to AJCC) [12] and form the body of the analysis in the present study. Written informed consent was obtained from the patients for publication of this report and any accompanying images.

Pre-treatment work-up

Twenty-eight patients were studied by magnetic resonance imaging (MRI), and 34 by computed tomography (CT) scan. Ultrasound (US) examination was the only diagnostic tool employed before treatment for 10 patients. US-guided core biopsy (Gallini- Mantova, Italy) was performed in 44 cases (71%), which was diagnostic for AF in 37 patients and nondiagnostic in the remaining 7.

Surgical technique

Surgical principles that aided resection comprised a wide excision of the mass, which involved the removal of all gross disease together with a normal tissue rim of at least 1 cm whenever possible [13]. For this purpose, intraoperative frozen section (IFS) margin evaluation was employed in those cases that the operating surgeon deemed at risk of margin involvement. All operations were performed under antibiotic cover with third generation cephalosporin, which was continued until the suction drains were removed. Low molecular weight heparins were administered starting from the first pre-operative day and were continued for one month following surgery to prevent thromboembolic disease.

Pathology examination

Both the surgical specimen and margin biopsy where necessary were oriented by the surgeon and inked by the pathologist. In cases of IFS diagnosis, the pathologist

examined all the margins if the neoplasm was ill-defined or the closest margin to neoplasia in the case of a clearly recognizable mass. Biopsy specimens were analyzed in their entirety. If neoplastic cells were detected on the inked margin examined, further surgery was performed until negative microscopic margins were achieved [14]. A histological diagnosis of aggressive fibromatosis was obtained in all operated cases. Whenever deemed necessary, appropriate immunohistology was performed as an adjunct to the morphological evaluation of the neoplasia. Tumor characteristics studied included site and size: the size was obtained by measuring the largest dimension of the tumor in the surgical specimen and by MRI or CT scan for non-operated patients.

Follow-up and recurrence

Follow-up was by outpatient clinical appointments, with clinical and radiological assessment as indicated. Recurrence was diagnosed radiologically and confirmed by percutaneous biopsy when appropriate. No patient was lost to follow-up.

Statistical analysis

The Chi-square test and the Fisher exact test were used, as appropriate, to compare distributions of categorical variables. The crude cumulative incidence of tumor recurrences was computed in a competing risk framework, with deaths without recurrence treated as competing events. Cumulative incidences were compared across subgroups by means of the Gray test. A multivariable Cox regression model was used to test the independent prognostic value of the variables which showed significant results in the univariate analysis. Adjusted hazard ratios (HR) with 95% confidence intervals (CIs) were reported. All analyses were carried out with the SAS software (SAS Institute, Cary, NC, USA) and the R (<http://cran.r-project.org/>) software. All the reported *P*-values were two-sided.

Results

There were 43 females and 19 males (median age 36 years, range 16 to 76 years) affected by primary (52) or recurrent (10) disease. In order to optimize surgical outcome (at least 1 cm of free margin whenever possible) intraoperative frozen section (IFS) evaluation was employed in 17 cases. In six of these cases it was performed twice because the first IFS examination reported a microscopically involved margin. Definitive pathology examination confirmed an R0 situation in 49 patients and R1 in 13 patients. No cases of discordance between the last intraoperative and the final margin evaluation (R0 vs R1) were registered among the 17 patients who had IFS evaluation (Table 1). The probability of receiving IFS evaluation was not correlated to the tumor size (3 of

Table 1 Factors associated with the achievement of R0 surgery for the 62 radically resected patients

Variable	Classification	R0 N = 49	R1 N = 13	P-value
Age	≤36	24 (77.4)	7 (22.6)	0.76
	>36	25 (80.7)	6 (19.4)	
Gender	M	15 (78.9)	4 (21.1)	1.00
	F	34 (79.1)	9 (20.9)	
Recurrence at presentation	Yes	8 (80.0)	2 (20.0)	1.00
	No	41 (78.8)	11 (21.2)	
Site of tumor	Trunk	33 (78.6)	9 (21.4)	0.35
	Head and neck	4 (57.1)	3 (42.9)	
	Limbs	6 (85.7)	1 (14.3)	
	Mesentery	6 (100)	0 (0.0)	
Limb localization	Yes	6 (85.7)	1 (14.3)	1.00
	No	43 (78.2)	12 (21.8)	
Tumor maximum diameter	<10 cm	40 (80.0)	10 (20.0)	0.70
	≥10 cm	9 (75.0)	3 (25.0)	
IFS*	No	32 (71.1)	13 (28.9)	0.01
	Yes	17 (100.0)	0 (0.0)	
Postoperative RT [§]	No	46 (83.6)	9 (16.4)	0.03
	Yes	3 (42.9)	4 (57.1)	

*IFS, intraoperative frozen sections; [§]RT, radiotherapy.

12 vs 14 of 50 for <10 cm vs ≥10 cm respectively, $P=0.83$). R1 patients were more likely to receive post-operative radiotherapy (Table 1).

Follow-up and survival

After a median follow-up time of 66 months (range 2 to 175) two deaths related to the disease were registered. These deaths were not caused by recurrence of the disease, but by long-term complications of treatment. In one case, a 30 year-old male patient affected by a huge intra-abdominal recurrent desmoid, who underwent radical surgery at our institute, died after 14 months because of rejection after small bowel transplantation. The other case was a 54 year-old male affected by a cervico-thoracic desmoid, who underwent a huge demolition of the thoracic wall and pulmonary resection, followed by radiotherapy as a result of the pathology findings of R1 surgery, and developed a pulmonary mycetoma that was resected 32 months after the primary surgery. He died from subsequent complications four months thereafter. Three other patients died during follow-up due to causes other than fibromatosis (one for cardiovascular event, the other two for advanced colorectal cancer). For these reasons, actuarial five-year overall survival was 95% in our series.

Risk factors affecting cumulative recurrence (CR)

Seven patients developed recurrence during follow-up that arose within the surgical field in four cases, and

within the same anatomical region, but distant from the surgical field, in the remaining three patients. Of these seven patients, three underwent repeated surgery that was demonstrated to be R0 in all three cases. At this time all three patients are alive and disease-free. None of the patients who had IFS examination developed recurrence during follow-up.

Actuarial CR was 8%, 13%, 16% at three to five and eight years respectively. Univariate analysis of possible factors affecting CR is reported in Table 2. R1 surgery, (Figure 1), tumor maximum diameter ≥10 cm and limb localization (vs any other) (Figure 2) were associated with significantly higher CR rates. Patients who had IFS margin evaluation showed a significantly lower CR (no recurrences in that group) in comparison with patients who did not have such an assessment (Figure 3). In multivariate analysis only limb localization was significantly associated with higher CR (Table 3).

Discussion

Despite the rarity of this disease, several reports exist on prognostic factors for recurrence after resection of AF [15-24]. However, to minimize recurrence, clear indications on how to perform surgery and analyze AF specimens are lacking. In the current single-center study, R1 surgery, tumor diameter (≥10 cm) and limb localization were the most significant prognostic factors associated with higher CR in a consecutive series of desmoid tumors. The achievement of a microscopically negative

Table 2 Factors affecting CR rate for the 62 patients who underwent macroscopically radical tumor resection

Variable	Classification	At risk	Recurrences (% 5-year cumulative incidence)	P-value
All patients		62	7 (12.8)	
Age	≤36	31	5 (19.2)	0.30
	>36	31	2 (5.0)	
Gender	M	19	2 (13.1)	0.74
	F	43	5 (12.2)	
Recurrence at presentation	Yes	10	3 (10.6)	0.17
	No	52	4 (20.0)	
Site of tumor	Trunk	42	1 (7.8)	0.09
	Head and neck	7	1 (16.7)	
	Limbs	7	3 (33.3)	
	Mesentery	6	2 (16.7)	
Limb localization	Yes	7	3 (33.3)	0.02
	No	55	4 (9.9)	
Residual tumor	R0	49	4 (7.1)	0.04
	R1	13	3 (46.4)	
Tumor maximum diameter	<10 cm	50	4 (8.1)	0.05
	≥10 cm	12	3 (31.8)	
IFS*	No	45	7 (19.1)	0.04
	Yes	17	0 (0.0)	

*IFS, intraoperative frozen sections.

resection margin assessed by IFS was an accurate predictor of R0 resection and lower CR, where none of the 17 negative IFS specimens was demonstrated to have microscopic infiltration of the margin at definitive pathology stain and none of the patients receiving IFS developed recurrence. This finding is limited by the lack of randomization and by the fact that IFS was employed in only 27% of patients from our series, so that we do not have sufficient data supporting a further reduction of R1 cases with increased use of IFS. Strict cooperation between the team of doctors involved in the management of this disease is of particular importance in achieving successful R0 surgery. The anatomical surgery should be accurately evaluated for a more complete radicality, and the margin at risk of involvement clearly indicated by the surgeon to the pathologist. In addition, pathologists should be fully aware of the characteristics of the disease that they are dealing with, which is often infiltrating, and of any previous treatment, such as radiotherapy or surgery, in order to better interpret any findings of fibrosis, inflammatory cells or cellular atypia in particular at the time when a correct margin definition is needed.

The impact of a negative surgical margin after surgery for desmoid tumors has been widely debated in the literature. In a recently published French study [15], the largest series of sporadic desmoids, progression-free survival curves were not significantly different in terms of

microscopic assessment of surgical resection quality (R0 vs R1), although R2 resections showed a significantly poorer prognosis. This French study, which retrospectively entered into a database the data of 426 patients from 24 participating centers starting from 1965, showed a five-year progression-free survival rate of 62.5% for R0 resections, which compares unfavorably with our figure of 92.9%. This difference is difficult to explain, but if we consider that RFS rates for R1 cases are quite similar (60.5% vs 53.6%), it is arguable that in a large multicentric study enrolling very early cases, a problem may be the lack of standardization mainly for pathological assessment of margins (for example, definition of “R0” and “R1” resections). In the study conducted by the Italian National Tumour Institute (INT) [16], the presence of microscopic disease in one surgical margin assumed prognostic relevance in patients with an already recurrent disease but not in patients with primary lesions. Indeed, data from Memorial Sloan-Kettering Cancer Centre (MSKCC) [17], Mirabell *et al.* [18], Reitamo *et al.* [19] made the same observations. Conversely, and in line with our data, other authors [20-22] identified a positive resection margin as the most important independent predictive factor of local recurrence.

We identify the subgroup of patients affected by AF limb localizations to be at risk for recurrence even after radical surgery. This finding is similar to that of several




Figure 1 Impact of R0 vs R1 surgery on CR for the 62 patients.

other reports [15,16,21,22]. In the study carried out by the University of Texas [23] (UTMDACC) authors compared two consecutive series of desmoids tumors investigating differences of approach and outcome between an earlier group of patients treated from 1965 to 1994 and

a recent group treated from 1995 to 2005. Interestingly, in the most recent series only extremity site and age ≤ 30 were prognostic factors for recurrence. Although in that group patients with positive margins were generally more likely to undergo adjuvant therapy (53% vs 23%),




Figure 2 Impact of tumor localization (limbs vs no limbs).




Figure 3 Impact of performing IFS on CR.

the interseries comparison highlighted significant improvement in disease-free survival in the recent series, even in the presence of a higher rate of positive margins.

Objective evaluation of efficacy is affected by the lack of prospective studies comparing local recurrence in comparison to, or in combination with, surgery. For radiotherapy, in the presence of microscopically positive margins, improved recurrence-free survival reported by UTMDACC [23] and Massachusetts General Hospital (MGH) [24] is counterbalanced by negative findings of MSKCC [17] and INT [16] studies. The indication for adjuvant radiotherapy for each patient of our series was evaluated within a framework of a multidisciplinary team comprising surgeons and radiotherapists. This resulted in a significantly higher probability for patients who underwent R1 surgery to receive postoperative radiotherapy (3 of 49 after R0 vs 4 of 13 after R1 surgery, Table 1).

The good results after R0 surgery in this series are to be considered in the light of the relatively high all-causes mortality that occurred during follow-up, despite the median age of the whole group of patients being

36 years. In particular, two patients died from causes directly related to the tumor treatment, and these data deserve careful consideration if we assume that even observation alone proved to be an effective option in high-risk patients [10,11].

Conclusions

R0 surgery aided by IFS can decrease CR rate in patients with AF. For patients with tumors confined to the limbs, a particularly strict follow-up or non-surgical treatment could be appropriate because of the high risk of recurrence after R0 surgery in this subgroup. In selected cases, watchful waiting with close clinical follow-up could represent a viable strategy for limb tumors smaller than 5 cm [10,11]. Indeed, as the peculiar epidemiology of this tumor is unlikely to empower generous trial design, systematic risk weighting of individual components is, therefore, the most reasonable way to stratify patients and define a rationale for approaches other than surgery or in combination with it.

Abbreviations

AF: Aggressive fibromatosis; AJCC: American Joint Committee on Cancer; APC: Adenomatous polyposis coli; CR: Cumulative recurrence; FAP: Familial adenomatous polyposis; IFS: Intraoperative frozen sections; INT: Istituto Nazionale dei Tumori; MGH: Massachusetts General Hospital; MRI: Magnetic resonance imaging; MSKCC: Memorial Sloan-Kettering Cancer Center; US: Ultrasound; UTMDACC: University of Texas MD Anderson Cancer Center.

Competing interests

All of the authors of this manuscript declared that no financial or non-financial interests were related to this study or future application after publication.

Table 3 Multivariate analysis of factors affecting CR

	HR	95 % CI	P-value
Limb localization*	1.71	1.03 to 2.84	0.04
R1 surgery[§]	2.94	0.47 to 18.20	0.25
Tumor size (≥10 cm)	2.68	0.43 to 16.67	0.29

Abbreviation: HR, hazard ratio.

*Limbs vs all other localizations.

[§]R1 vs R0 surgery.

Authors' contributions

EBe was responsible for manuscript writing and study design. AT, AC and RB gave comments and revised the manuscript. PM, EBo and BB were responsible for data acquisition and analysis. GV, GM and GC were in charge of correction of the manuscript, while TD, FV and BA collaborated on the whole project design. All authors read and approved the final manuscript.

Acknowledgements

We thank Cecilia Margarino, Bruno Montanari and all the Tumor Registry staff of the European Institute of Oncology for their support on this study. We thank also William Russell-Edu for help with revising the English of this text and Mrs Nordiana Baruzzi.

Author details

¹Division of General and Laparoscopic Surgery, European Institute of Oncology, Via G. Ripamonti, 435, 20141, Milan, Italy. ²Division of Melanoma and Muscle-Cutaneous Sarcomas, European Institute of Oncology, Via G. Ripamonti, 435, 20141, Milan, Italy. ³University of Milan, Milan, Italy. ⁴Division of Abdomino-Pelvic Surgery, European Institute of Oncology, Via G. Ripamonti, 435, 20141, Milan, Italy. ⁵Division of Pathology, European Institute of Oncology, Via G. Ripamonti, 435, 20141, Milan, Italy. ⁶Division of Medical Oncology, European Institute of Oncology, Via G. Ripamonti, 435, 20141, Milan, Italy. ⁷Division of Epidemiology and Biostatistics, European Institute of Oncology, Via G. Ripamonti, 435, 20141, Milan, Italy.

Received: 24 May 2012 Accepted: 15 August 2012

Published: 10 September 2012

References

- Li M, Cordon-Cardo C, Gerald WL, Rosai J: **Desmoid fibromatosis is a clonal process.** *Hum Pathol* 1996, **27**:939-943.
- Escobar C, Munker R, Thomas JO, Li BD, Burton GV: **Update on desmoid tumors.** *Ann Oncol* 2011, **23**:562-569.
- Rüdiger HA, Ngan SY, Ng M, Powell GJ, Choong PF: **Radiation therapy in the treatment of desmoid tumours reduces surgical indications.** *Eur J Surg Oncol* 2010, **36**:84-88.
- Gluck I, Griffith KA, Biermann JS, Feng FY, Lucas DR, Ben-Josef E: **Role of radiotherapy in the management of desmoid tumors.** *Int J Radiat Oncol Biol Phys* 2011, **80**:787-792.
- Nishida Y, Tsukushi S, Shido Y, Wasa J, Ishiguro N, Yamada Y: **Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study.** *J Clin Oncol* 2010, **28**:107-109.
- Kasper B, Ströbel P, Hohenberger P: **Desmoid tumors: clinical features and treatment options for advanced disease.** *Oncologist* 2011, **16**:682-693.
- Gega M, Yanagi H, Yoshikawa R, Noda M, Ikeuchi H, Tsukamoto K, Oshima T, Fujiwara Y, Gondo N, Tamura K, Utsunomiya J, Hashimoto-Tamaoki T, Yamamura T: **Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis.** *J Clin Oncol* 2006, **24**:102-105.
- Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I: **Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.** *Eur J Cancer* 2009, **45**:2930-2934.
- Penel N, Le Cesne A, Bui BN, Perol D, Brain EG, Ray-Coquard I, Guillemet C, Chevreau C, Cupissol D, Chabaud S, Jimenez M, Duffaud F, Piperno-Neumann S, Mignot L, Blay JY: **Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.** *Ann Oncol* 2011, **22**:452-457.
- Bonvalot S, Eldweny H, Haddad V, Rimareix F, Missenard G, Oberlin O, Vanel D, Terrier P, Blay JY, Le Cesne A, Le Péchoux C: **Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients.** *Eur J Surg Oncol* 2008, **34**:462-468.
- Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Péchoux C, Casali PG, Le Cesne A, Gronchi A, Bonvalot S: **Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment.** *Ann Surg Oncol* 2009, **16**:2587-2593.
- Edge SB, Bird DR, Compton CC, Fritz AG, Greene FL, Trotti A: *AJCC Cancer Staging Manual*. 7th edition. Berlin: Springer; 2010.
- Bertani E, Chiappa A, Testori A, Mazzarol G, Biffi R, Martella S, Pace U, Soteldo J, Vigna PD, Lembo R, Andreoni B: **Desmoid tumors of the anterior**

- abdominal wall: results from a monocentric surgical experience and review of the literature.** *Ann Surg Oncol* 2009, **16**:1642-1649.
- Zhang P, Brooks JS: **Modern pathological evaluation of soft tissue sarcoma specimens and its potential role in soft tissue sarcoma research.** *Curr Treat Options Oncol* 2004, **5**:441-450.
- Salas S, Dufresne A, Bui B, Blay JY, Terrier P, Ranchere-Vince D, Bonvalot S, Stoeckle E, Guillou L, Le Cesne A, Oberlin O, Brouste V, Coindre JM: **Prognostic Factors Influencing Progression-Free Survival Determined From a Series of Sporadic Desmoid Tumors: A Wait-and-See Policy According to Tumor Presentation.** *J Clin Oncol* 2011, **29**:3553-3558.
- Gronchi A, Casali PG, Mariani L, Lo Vullo S, Coecchia M, Lozza L, Bertulli R, Fiore M: **Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution.** *J Clin Oncol* 2003, **21**:1390-1397.
- Merchant NB, Lewis JJ, Woodruff JM, Leung DH, Brennan MF: **Extremity and trunk desmoid tumours: a multifactorial analysis of outcome.** *Cancer* 1999, **86**:2045-2052.
- Mirabell R, Suit H, Mankin HJ: **Fibromatoses: from postsurgical surveillance to combined surgery and radiation therapy.** *Int J Radiat Oncol Biol Phys* 1990, **18**:535-540.
- Reitamo JJ, Scheinin TM, Hayry P: **The desmoid syndrome: new aspects in the cause, pathogenesis and treatment of the desmoid tumour.** *Am J Surg* 1986, **151**:230-237.
- Huang K, Fu H, Shi YQ, Zhou Y, Du CY: **Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution.** *J Surg Oncol* 2009, **100**:563-569.
- Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA: **Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy.** *J Clin Oncol* 1999, **17**:158-167.
- Stoeckle E, Coindre JM, Longy M, Binh MB, Kantor G, Kind M, de Lara CT, Avril A, Bonichon F, Bui BN: **A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases.** *Eur J Surg Oncol* 2009, **35**:129-134.
- Lev D, Kotilingam D, Wei C, Ballo MT, Zagars GK, Pisters PWT, Lazar AA, Patel SR, Benjamin RS, Pollock RE: **Optimizing treatment of desmoid tumors.** *J Clin Oncol* 2007, **25**:1785-1791.
- Spear MA, Jennings LC, Mankin HJ, Spiro IJ, Springfield DS, Gebhardt MC, Rosenberg AE, Efid JT, Suit HD: **Individualizing management of aggressive fibromatoses.** *Int J Radiat Oncol Biol Phys* 1998, **40**:637-645.

doi:10.1186/1477-7819-10-184

Cite this article as: Bertani et al.: Recurrence and prognostic factors in patients with aggressive fibromatosis. The role of radical surgery and its limitations. *World Journal of Surgical Oncology* 2012 **10**:184.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

